Reading Time: 5 minutesIn a previous blog, we looked at DNA, genes and proteins. This blog dives deeper into this area of biology and focuses on how proteins
Tag: SOD1
34th Symposium: Basel Causes and disease mechanisms Clinical Trials Events Genetic Research Healthcare Markers of Disease Progression MND Research Symposium Treatments
Reuniting the MND community at the 34th International Symposium on ALS/MND
Reading Time: 4 minutesAfter 3 years of online events, the MND research and healthcare community reunited in-person at the 34th International Symposium on ALS/MND in Basel, Switzerland! From
Reading Time: 5 minutesThe MND clinical trial landscape has grown vastly over the last decade and this has led to increased opportunities for people with MND to take
Reading Time: 4 minutesLast year was a really exciting year for MND clinical trials, with more trials recruiting in the UK than ever before, some promising results being
Reading Time: 6 minutesIt has been suggested that there might be a pre-symptomatic stage of MND, where the disease is active and occurring within a person but no symptoms are showing. There is currently little research in this area and a lack of evidence of a pre-symptomatic stage of the disease. However, if it can be shown that there is a pre-symptomatic stage which can be measured, this could be very useful in helping people with MND to get treatment as early as possible. Dr Michael Benatar, from the University of Miami, has been looking into this by studying the development of MND and how the disease presents in people who have a high risk of developing it.
Reading Time: 6 minutesAs part of our Symposium Spotlight series, we’re looking back on some of the research presented at the 32nd International Symposium on ALS/MND. This blog
Reading Time: 4 minutesThis is blog number 5 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green text correspond
Reading Time: 5 minutesThis is blog number two in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green text correspond
Reading Time: 7 minutesGlobal biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in
Reading Time: 6 minutesEach year, MND Associations across the globe mark 21 June as a special day of recognition, acknowledging the impact that MND has on people around